nodes	percent_of_prediction	percent_of_DWPC	metapath
Fenoldopam—DRD5—eyelid—melanoma	0.046	0.655	CbGeAlD
Fenoldopam—Transaminases increased—Carmustine—melanoma	0.00874	0.0421	CcSEcCtD
Fenoldopam—Leukocytosis—Carmustine—melanoma	0.00566	0.0272	CcSEcCtD
Fenoldopam—Injection site reaction—Carmustine—melanoma	0.00529	0.0254	CcSEcCtD
Fenoldopam—Back pain—Vemurafenib—melanoma	0.00425	0.0205	CcSEcCtD
Fenoldopam—Myocardial ischaemia—Docetaxel—melanoma	0.00425	0.0205	CcSEcCtD
Fenoldopam—Nasal congestion—Temozolomide—melanoma	0.00409	0.0197	CcSEcCtD
Fenoldopam—Oliguria—Docetaxel—melanoma	0.00371	0.0178	CcSEcCtD
Fenoldopam—Hypokalaemia—Carmustine—melanoma	0.00351	0.0169	CcSEcCtD
Fenoldopam—Injection site reaction—Docetaxel—melanoma	0.0034	0.0163	CcSEcCtD
Fenoldopam—Hypokalaemia—Temozolomide—melanoma	0.00339	0.0163	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Bleomycin—melanoma	0.00336	0.0162	CcSEcCtD
Fenoldopam—Hypotension—Vemurafenib—melanoma	0.00335	0.0161	CcSEcCtD
Fenoldopam—Myocardial infarction—Bleomycin—melanoma	0.00334	0.0161	CcSEcCtD
Fenoldopam—Haemoglobin—Bleomycin—melanoma	0.00307	0.0148	CcSEcCtD
Fenoldopam—Constipation—Vemurafenib—melanoma	0.00307	0.0148	CcSEcCtD
Fenoldopam—Haemorrhage—Bleomycin—melanoma	0.00306	0.0147	CcSEcCtD
Fenoldopam—DRD5—head—melanoma	0.00291	0.0414	CbGeAlD
Fenoldopam—Urinary tract infection—Carmustine—melanoma	0.00289	0.0139	CcSEcCtD
Fenoldopam—Flushing—Bleomycin—melanoma	0.00284	0.0137	CcSEcCtD
Fenoldopam—Body temperature increased—Vemurafenib—melanoma	0.00284	0.0136	CcSEcCtD
Fenoldopam—Urinary tract infection—Temozolomide—melanoma	0.00279	0.0134	CcSEcCtD
Fenoldopam—Haemoglobin—Carmustine—melanoma	0.00268	0.0129	CcSEcCtD
Fenoldopam—Haemorrhage—Carmustine—melanoma	0.00267	0.0129	CcSEcCtD
Fenoldopam—Flushing—Dactinomycin—melanoma	0.00265	0.0127	CcSEcCtD
Fenoldopam—Haemoglobin—Temozolomide—melanoma	0.00259	0.0125	CcSEcCtD
Fenoldopam—Haemorrhage—Temozolomide—melanoma	0.00258	0.0124	CcSEcCtD
Fenoldopam—Cardiac failure—Docetaxel—melanoma	0.00254	0.0122	CcSEcCtD
Fenoldopam—Flushing—Carmustine—melanoma	0.00248	0.0119	CcSEcCtD
Fenoldopam—Diarrhoea—Vemurafenib—melanoma	0.00245	0.0118	CcSEcCtD
Fenoldopam—Flushing—Temozolomide—melanoma	0.00239	0.0115	CcSEcCtD
Fenoldopam—ADRA1B—head—melanoma	0.00238	0.0339	CbGeAlD
Fenoldopam—Dizziness—Vemurafenib—melanoma	0.00237	0.0114	CcSEcCtD
Fenoldopam—ADRA1D—head—melanoma	0.00233	0.0332	CbGeAlD
Fenoldopam—DRD2—eye—melanoma	0.00231	0.0329	CbGeAlD
Fenoldopam—DRD2—retina—melanoma	0.00229	0.0326	CbGeAlD
Fenoldopam—Vomiting—Vemurafenib—melanoma	0.00228	0.011	CcSEcCtD
Fenoldopam—Chest pain—Bleomycin—melanoma	0.00227	0.0109	CcSEcCtD
Fenoldopam—Orthostatic hypotension—Docetaxel—melanoma	0.00227	0.0109	CcSEcCtD
Fenoldopam—Back pain—Carmustine—melanoma	0.00225	0.0108	CcSEcCtD
Fenoldopam—Headache—Vemurafenib—melanoma	0.00225	0.0108	CcSEcCtD
Fenoldopam—DRD1—head—melanoma	0.00222	0.0316	CbGeAlD
Fenoldopam—Back pain—Temozolomide—melanoma	0.00217	0.0105	CcSEcCtD
Fenoldopam—Nausea—Vemurafenib—melanoma	0.00213	0.0103	CcSEcCtD
Fenoldopam—Angina pectoris—Docetaxel—melanoma	0.00209	0.0101	CcSEcCtD
Fenoldopam—Hypotension—Bleomycin—melanoma	0.00203	0.00977	CcSEcCtD
Fenoldopam—Palpitations—Temozolomide—melanoma	0.00198	0.00955	CcSEcCtD
Fenoldopam—Chest pain—Carmustine—melanoma	0.00198	0.00952	CcSEcCtD
Fenoldopam—Anxiety—Carmustine—melanoma	0.00197	0.00949	CcSEcCtD
Fenoldopam—Dyspnoea—Bleomycin—melanoma	0.00194	0.00932	CcSEcCtD
Fenoldopam—Anxiety—Temozolomide—melanoma	0.00191	0.00917	CcSEcCtD
Fenoldopam—Acute coronary syndrome—Docetaxel—melanoma	0.00188	0.00907	CcSEcCtD
Fenoldopam—Myocardial infarction—Docetaxel—melanoma	0.00187	0.00902	CcSEcCtD
Fenoldopam—Tachycardia—Carmustine—melanoma	0.00185	0.00891	CcSEcCtD
Fenoldopam—ADRA2C—mammalian vulva—melanoma	0.00178	0.0254	CbGeAlD
Fenoldopam—Hypotension—Carmustine—melanoma	0.00177	0.00853	CcSEcCtD
Fenoldopam—Hyperhidrosis—Temozolomide—melanoma	0.00177	0.00853	CcSEcCtD
Fenoldopam—Haemoglobin—Docetaxel—melanoma	0.00172	0.0083	CcSEcCtD
Fenoldopam—Body temperature increased—Bleomycin—melanoma	0.00172	0.00827	CcSEcCtD
Fenoldopam—Haemorrhage—Docetaxel—melanoma	0.00172	0.00826	CcSEcCtD
Fenoldopam—Insomnia—Carmustine—melanoma	0.00172	0.00826	CcSEcCtD
Fenoldopam—Dyspnoea—Carmustine—melanoma	0.00169	0.00814	CcSEcCtD
Fenoldopam—Insomnia—Temozolomide—melanoma	0.00166	0.00798	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Dactinomycin—melanoma	0.00166	0.00798	CcSEcCtD
Fenoldopam—Dyspnoea—Temozolomide—melanoma	0.00163	0.00787	CcSEcCtD
Fenoldopam—Constipation—Carmustine—melanoma	0.00162	0.00781	CcSEcCtD
Fenoldopam—Body temperature increased—Dactinomycin—melanoma	0.0016	0.00771	CcSEcCtD
Fenoldopam—Abdominal pain—Dactinomycin—melanoma	0.0016	0.00771	CcSEcCtD
Fenoldopam—Flushing—Docetaxel—melanoma	0.00159	0.00766	CcSEcCtD
Fenoldopam—Constipation—Temozolomide—melanoma	0.00157	0.00754	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Carmustine—melanoma	0.00155	0.00747	CcSEcCtD
Fenoldopam—Body temperature increased—Carmustine—melanoma	0.0015	0.00722	CcSEcCtD
Fenoldopam—Abdominal pain—Carmustine—melanoma	0.0015	0.00722	CcSEcCtD
Fenoldopam—Gastrointestinal pain—Temozolomide—melanoma	0.0015	0.00721	CcSEcCtD
Fenoldopam—Abdominal pain—Temozolomide—melanoma	0.00145	0.00697	CcSEcCtD
Fenoldopam—Body temperature increased—Temozolomide—melanoma	0.00145	0.00697	CcSEcCtD
Fenoldopam—Back pain—Docetaxel—melanoma	0.00144	0.00695	CcSEcCtD
Fenoldopam—Muscle spasms—Docetaxel—melanoma	0.00144	0.00691	CcSEcCtD
Fenoldopam—ADRA2A—mammalian vulva—melanoma	0.00142	0.0203	CbGeAlD
Fenoldopam—Diarrhoea—Dactinomycin—melanoma	0.00139	0.00667	CcSEcCtD
Fenoldopam—Vomiting—Bleomycin—melanoma	0.00138	0.00665	CcSEcCtD
Fenoldopam—ADRA1A—head—melanoma	0.00134	0.0191	CbGeAlD
Fenoldopam—Palpitations—Docetaxel—melanoma	0.00132	0.00635	CcSEcCtD
Fenoldopam—DRD2—head—melanoma	0.00131	0.0187	CbGeAlD
Fenoldopam—Diarrhoea—Carmustine—melanoma	0.0013	0.00625	CcSEcCtD
Fenoldopam—Nausea—Bleomycin—melanoma	0.00129	0.00621	CcSEcCtD
Fenoldopam—Vomiting—Dactinomycin—melanoma	0.00129	0.0062	CcSEcCtD
Fenoldopam—ADRA2C—head—melanoma	0.00128	0.0182	CbGeAlD
Fenoldopam—Chest pain—Docetaxel—melanoma	0.00127	0.00612	CcSEcCtD
Fenoldopam—Dizziness—Carmustine—melanoma	0.00125	0.00604	CcSEcCtD
Fenoldopam—Diarrhoea—Temozolomide—melanoma	0.00125	0.00604	CcSEcCtD
Fenoldopam—Dizziness—Temozolomide—melanoma	0.00121	0.00583	CcSEcCtD
Fenoldopam—Vomiting—Carmustine—melanoma	0.00121	0.0058	CcSEcCtD
Fenoldopam—Nausea—Dactinomycin—melanoma	0.0012	0.00579	CcSEcCtD
Fenoldopam—Tachycardia—Docetaxel—melanoma	0.00119	0.00573	CcSEcCtD
Fenoldopam—Headache—Carmustine—melanoma	0.00119	0.00572	CcSEcCtD
Fenoldopam—Vomiting—Temozolomide—melanoma	0.00117	0.00561	CcSEcCtD
Fenoldopam—Headache—Temozolomide—melanoma	0.00115	0.00553	CcSEcCtD
Fenoldopam—Hypotension—Docetaxel—melanoma	0.00114	0.00548	CcSEcCtD
Fenoldopam—Nausea—Carmustine—melanoma	0.00113	0.00542	CcSEcCtD
Fenoldopam—Insomnia—Docetaxel—melanoma	0.0011	0.00531	CcSEcCtD
Fenoldopam—Nausea—Temozolomide—melanoma	0.00109	0.00524	CcSEcCtD
Fenoldopam—Dyspnoea—Docetaxel—melanoma	0.00109	0.00523	CcSEcCtD
Fenoldopam—Constipation—Docetaxel—melanoma	0.00104	0.00502	CcSEcCtD
Fenoldopam—ADRA2A—head—melanoma	0.00102	0.0145	CbGeAlD
Fenoldopam—Gastrointestinal pain—Docetaxel—melanoma	0.000997	0.0048	CcSEcCtD
Fenoldopam—Body temperature increased—Docetaxel—melanoma	0.000964	0.00464	CcSEcCtD
Fenoldopam—Abdominal pain—Docetaxel—melanoma	0.000964	0.00464	CcSEcCtD
Fenoldopam—ADRA2C—lymph node—melanoma	0.000893	0.0127	CbGeAlD
Fenoldopam—Diarrhoea—Docetaxel—melanoma	0.000834	0.00401	CcSEcCtD
Fenoldopam—Dizziness—Docetaxel—melanoma	0.000806	0.00388	CcSEcCtD
Fenoldopam—Vomiting—Docetaxel—melanoma	0.000775	0.00373	CcSEcCtD
Fenoldopam—Headache—Docetaxel—melanoma	0.000764	0.00368	CcSEcCtD
Fenoldopam—Nausea—Docetaxel—melanoma	0.000724	0.00349	CcSEcCtD
Fenoldopam—ADRA2A—lymph node—melanoma	0.000713	0.0102	CbGeAlD
Fenoldopam—DRD1—Signaling Pathways—MMP9—melanoma	4.19e-05	5.81e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CD—melanoma	4.18e-05	5.79e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—CDKN1A—melanoma	4.18e-05	5.79e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—MAPK1—melanoma	4.17e-05	5.78e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—EGFR—melanoma	4.17e-05	5.78e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—PTEN—melanoma	4.17e-05	5.77e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—NFKB1—melanoma	4.15e-05	5.75e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PTEN—melanoma	4.15e-05	5.75e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—PIK3CA—melanoma	4.14e-05	5.74e-05	CbGpPWpGaD
Fenoldopam—DRD2—GPCR downstream signaling—PIK3CA—melanoma	4.14e-05	5.73e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—MMP9—melanoma	4.14e-05	5.73e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CXCL8—melanoma	4.13e-05	5.72e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MDM2—melanoma	4.13e-05	5.72e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—CDKN1A—melanoma	4.12e-05	5.71e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—PTEN—melanoma	4.11e-05	5.7e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—HRAS—melanoma	4.1e-05	5.68e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—HRAS—melanoma	4.1e-05	5.67e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—NFKB1—melanoma	4.09e-05	5.67e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—KRAS—melanoma	4.09e-05	5.67e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—PIK3CA—melanoma	4.08e-05	5.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—MAPK3—melanoma	4.08e-05	5.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—ERBB2—melanoma	4.07e-05	5.63e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling by GPCR—AKT1—melanoma	4.07e-05	5.63e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MDM2—melanoma	4.06e-05	5.63e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MAP2K1—melanoma	4.05e-05	5.61e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CDKN1B—melanoma	4.03e-05	5.59e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CD—melanoma	4.03e-05	5.58e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PIK3CB—melanoma	4.02e-05	5.56e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling by GPCR—AKT1—melanoma	4.01e-05	5.56e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—ERBB2—melanoma	4e-05	5.55e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—FGF2—melanoma	4e-05	5.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—BRAF—melanoma	4e-05	5.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—GPCR downstream signaling—AKT1—melanoma	3.99e-05	5.53e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—GPCR downstream signaling—PIK3CA—melanoma	3.99e-05	5.52e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CASP3—melanoma	3.95e-05	5.48e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PIK3CB—melanoma	3.95e-05	5.47e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—IL2—melanoma	3.95e-05	5.47e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—KRAS—melanoma	3.94e-05	5.46e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—IL6—melanoma	3.93e-05	5.44e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—IL6—melanoma	3.92e-05	5.43e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PIK3CB—melanoma	3.9e-05	5.4e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IGF1—melanoma	3.9e-05	5.4e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—MAPK1—melanoma	3.88e-05	5.37e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—EGFR—melanoma	3.88e-05	5.37e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PTGS2—melanoma	3.86e-05	5.35e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CXCL8—melanoma	3.86e-05	5.34e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—FGF2—melanoma	3.86e-05	5.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CCND1—melanoma	3.85e-05	5.33e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—HRAS—melanoma	3.83e-05	5.31e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CTNNB1—melanoma	3.81e-05	5.28e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CXCL8—melanoma	3.8e-05	5.26e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—HRAS—melanoma	3.77e-05	5.23e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CDKN1B—melanoma	3.77e-05	5.22e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MAP2K1—melanoma	3.77e-05	5.22e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—VEGFA—melanoma	3.77e-05	5.22e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—PIK3CA—melanoma	3.76e-05	5.21e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MDM2—melanoma	3.74e-05	5.19e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CD—melanoma	3.74e-05	5.18e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—MMP9—melanoma	3.74e-05	5.17e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—STAT3—melanoma	3.73e-05	5.16e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—GPCR downstream signaling—AKT1—melanoma	3.73e-05	5.16e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—CDKN1A—melanoma	3.72e-05	5.16e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—NRAS—melanoma	3.72e-05	5.15e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—VEGFA—melanoma	3.72e-05	5.15e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PTEN—melanoma	3.71e-05	5.14e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CDKN1B—melanoma	3.71e-05	5.14e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—GPCR downstream signaling—PIK3CA—melanoma	3.71e-05	5.13e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—NFKB1—melanoma	3.7e-05	5.12e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CASP3—melanoma	3.69e-05	5.11e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—ERBB2—melanoma	3.69e-05	5.11e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—IL2—melanoma	3.69e-05	5.11e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—STAT3—melanoma	3.68e-05	5.1e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—NRAS—melanoma	3.67e-05	5.08e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—IL6—melanoma	3.67e-05	5.08e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—GPCR downstream signaling—AKT1—melanoma	3.67e-05	5.08e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—KRAS—melanoma	3.66e-05	5.07e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CB—melanoma	3.64e-05	5.05e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CASP3—melanoma	3.63e-05	5.03e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—IL2—melanoma	3.63e-05	5.03e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling by GPCR—AKT1—melanoma	3.62e-05	5.02e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—PIK3CA—melanoma	3.62e-05	5.02e-05	CbGpPWpGaD
Fenoldopam—DRD5—Signaling Pathways—AKT1—melanoma	3.62e-05	5.01e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—IL6—melanoma	3.61e-05	5e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MDM2—melanoma	3.61e-05	5e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CCND1—melanoma	3.59e-05	4.98e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—FGF2—melanoma	3.58e-05	4.96e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—MAPK3—melanoma	3.56e-05	4.93e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CTNNB1—melanoma	3.56e-05	4.93e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—ERBB2—melanoma	3.56e-05	4.93e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CCND1—melanoma	3.54e-05	4.9e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—MAPK3—melanoma	3.52e-05	4.87e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CB—melanoma	3.51e-05	4.86e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CTNNB1—melanoma	3.5e-05	4.85e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CXCL8—melanoma	3.5e-05	4.85e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MMP9—melanoma	3.49e-05	4.83e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—HRAS—melanoma	3.48e-05	4.82e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—CDKN1A—melanoma	3.48e-05	4.82e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PTEN—melanoma	3.47e-05	4.81e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—MYC—melanoma	3.47e-05	4.8e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—NFKB1—melanoma	3.45e-05	4.78e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MMP9—melanoma	3.43e-05	4.76e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—CDKN1A—melanoma	3.42e-05	4.74e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CDKN1B—melanoma	3.42e-05	4.74e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—MYC—melanoma	3.42e-05	4.74e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PTEN—melanoma	3.41e-05	4.73e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—NFKB1—melanoma	3.4e-05	4.71e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—MAPK1—melanoma	3.39e-05	4.69e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—EGFR—melanoma	3.39e-05	4.69e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling by GPCR—AKT1—melanoma	3.38e-05	4.69e-05	CbGpPWpGaD
Fenoldopam—DRD2—GPCR downstream signaling—AKT1—melanoma	3.38e-05	4.68e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CXCL8—melanoma	3.37e-05	4.67e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PTEN—melanoma	3.37e-05	4.67e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—PIK3CA—melanoma	3.37e-05	4.66e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—VEGFA—melanoma	3.35e-05	4.65e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MDM2—melanoma	3.35e-05	4.64e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—HRAS—melanoma	3.35e-05	4.64e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CASP3—melanoma	3.35e-05	4.64e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—IL2—melanoma	3.35e-05	4.63e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—MAPK1—melanoma	3.34e-05	4.63e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—EGFR—melanoma	3.34e-05	4.63e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling by GPCR—AKT1—melanoma	3.33e-05	4.61e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—IL6—melanoma	3.33e-05	4.61e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—STAT3—melanoma	3.32e-05	4.6e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—NRAS—melanoma	3.31e-05	4.59e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—ERBB2—melanoma	3.3e-05	4.58e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CDKN1B—melanoma	3.29e-05	4.56e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CCND1—melanoma	3.26e-05	4.52e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CB—melanoma	3.26e-05	4.52e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—GPCR downstream signaling—AKT1—melanoma	3.26e-05	4.51e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CTNNB1—melanoma	3.23e-05	4.47e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CASP3—melanoma	3.23e-05	4.47e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—IL2—melanoma	3.22e-05	4.46e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—IL6—melanoma	3.21e-05	4.44e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—KRAS—melanoma	3.2e-05	4.43e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—MAPK3—melanoma	3.17e-05	4.4e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MMP9—melanoma	3.17e-05	4.39e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—KRAS—melanoma	3.16e-05	4.38e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—CDKN1A—melanoma	3.16e-05	4.37e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PTEN—melanoma	3.15e-05	4.36e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CCND1—melanoma	3.14e-05	4.35e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CXCL8—melanoma	3.13e-05	4.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—VEGFA—melanoma	3.13e-05	4.34e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NFKB1—melanoma	3.13e-05	4.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—HRAS—melanoma	3.11e-05	4.31e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CTNNB1—melanoma	3.11e-05	4.31e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—STAT3—melanoma	3.1e-05	4.3e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—NRAS—melanoma	3.1e-05	4.29e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—MYC—melanoma	3.09e-05	4.28e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—VEGFA—melanoma	3.08e-05	4.27e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling by GPCR—AKT1—melanoma	3.07e-05	4.25e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CDKN1B—melanoma	3.06e-05	4.24e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—STAT3—melanoma	3.05e-05	4.23e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MMP9—melanoma	3.05e-05	4.23e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—NRAS—melanoma	3.05e-05	4.22e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—CDKN1A—melanoma	3.04e-05	4.21e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PTEN—melanoma	3.03e-05	4.2e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—GPCR downstream signaling—AKT1—melanoma	3.03e-05	4.19e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—MAPK1—melanoma	3.02e-05	4.18e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—EGFR—melanoma	3.02e-05	4.18e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NFKB1—melanoma	3.02e-05	4.18e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CASP3—melanoma	3e-05	4.15e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IL2—melanoma	3e-05	4.15e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—IL6—melanoma	2.98e-05	4.13e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MAPK3—melanoma	2.96e-05	4.11e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling by GPCR—AKT1—melanoma	2.96e-05	4.1e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—PIK3CA—melanoma	2.94e-05	4.07e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—PIK3CA—melanoma	2.93e-05	4.05e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CCND1—melanoma	2.92e-05	4.04e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MAPK3—melanoma	2.92e-05	4.04e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—PIK3CA—melanoma	2.9e-05	4.02e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CTNNB1—melanoma	2.89e-05	4e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MYC—melanoma	2.88e-05	3.99e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—KRAS—melanoma	2.85e-05	3.95e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—TP53—melanoma	2.85e-05	3.94e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—VEGFA—melanoma	2.84e-05	3.94e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MYC—melanoma	2.84e-05	3.93e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MMP9—melanoma	2.83e-05	3.93e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—CDKN1A—melanoma	2.82e-05	3.91e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—MAPK1—melanoma	2.82e-05	3.91e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—EGFR—melanoma	2.82e-05	3.91e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PTEN—melanoma	2.82e-05	3.9e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—STAT3—melanoma	2.82e-05	3.9e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—NRAS—melanoma	2.81e-05	3.89e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—TP53—melanoma	2.81e-05	3.89e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NFKB1—melanoma	2.8e-05	3.88e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—MAPK1—melanoma	2.78e-05	3.84e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—EGFR—melanoma	2.78e-05	3.84e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling by GPCR—AKT1—melanoma	2.75e-05	3.81e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—VEGFA—melanoma	2.74e-05	3.79e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—HRAS—melanoma	2.72e-05	3.77e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—STAT3—melanoma	2.71e-05	3.76e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—NRAS—melanoma	2.71e-05	3.75e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MAPK3—melanoma	2.69e-05	3.73e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—HRAS—melanoma	2.69e-05	3.72e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—KRAS—melanoma	2.66e-05	3.69e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—KRAS—melanoma	2.62e-05	3.63e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—PIK3CA—melanoma	2.62e-05	3.63e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MYC—melanoma	2.62e-05	3.62e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—IL6—melanoma	2.6e-05	3.61e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MAPK3—melanoma	2.59e-05	3.59e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—IL6—melanoma	2.57e-05	3.56e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—MAPK1—melanoma	2.56e-05	3.54e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—EGFR—melanoma	2.56e-05	3.54e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—VEGFA—melanoma	2.55e-05	3.53e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—TP53—melanoma	2.53e-05	3.51e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MYC—melanoma	2.52e-05	3.49e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—STAT3—melanoma	2.52e-05	3.49e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—NRAS—melanoma	2.51e-05	3.48e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—MAPK1—melanoma	2.47e-05	3.42e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—EGFR—melanoma	2.47e-05	3.41e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—PIK3CA—melanoma	2.45e-05	3.39e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—HRAS—melanoma	2.42e-05	3.36e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—KRAS—melanoma	2.42e-05	3.35e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—PIK3CA—melanoma	2.41e-05	3.34e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MAPK3—melanoma	2.41e-05	3.33e-05	CbGpPWpGaD
Fenoldopam—DRD1—Signaling Pathways—AKT1—melanoma	2.4e-05	3.33e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Metabolism—AKT1—melanoma	2.39e-05	3.31e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—PIK3CA—melanoma	2.38e-05	3.29e-05	CbGpPWpGaD
Fenoldopam—ADRA1D—Signaling Pathways—AKT1—melanoma	2.37e-05	3.28e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—TP53—melanoma	2.37e-05	3.28e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MYC—melanoma	2.34e-05	3.24e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—TP53—melanoma	2.33e-05	3.23e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—KRAS—melanoma	2.33e-05	3.23e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—IL6—melanoma	2.32e-05	3.21e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—MAPK1—melanoma	2.29e-05	3.17e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—EGFR—melanoma	2.29e-05	3.17e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—HRAS—melanoma	2.26e-05	3.14e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—HRAS—melanoma	2.23e-05	3.09e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—PIK3CA—melanoma	2.22e-05	3.08e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—IL6—melanoma	2.17e-05	3e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—KRAS—melanoma	2.16e-05	3e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—TP53—melanoma	2.15e-05	2.98e-05	CbGpPWpGaD
Fenoldopam—ADRA2B—Signaling Pathways—AKT1—melanoma	2.14e-05	2.96e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—PIK3CA—melanoma	2.14e-05	2.96e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—IL6—melanoma	2.13e-05	2.95e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—TP53—melanoma	2.07e-05	2.87e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—HRAS—melanoma	2.05e-05	2.85e-05	CbGpPWpGaD
Fenoldopam—ADRA2C—Signaling Pathways—AKT1—melanoma	2e-05	2.77e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—PIK3CA—melanoma	1.99e-05	2.75e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—HRAS—melanoma	1.98e-05	2.74e-05	CbGpPWpGaD
Fenoldopam—ADRA1B—Signaling Pathways—AKT1—melanoma	1.97e-05	2.73e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—IL6—melanoma	1.97e-05	2.72e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Metabolism—AKT1—melanoma	1.94e-05	2.69e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—TP53—melanoma	1.92e-05	2.66e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—IL6—melanoma	1.89e-05	2.62e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—HRAS—melanoma	1.84e-05	2.55e-05	CbGpPWpGaD
Fenoldopam—DRD2—Signaling Pathways—AKT1—melanoma	1.81e-05	2.51e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—IL6—melanoma	1.76e-05	2.44e-05	CbGpPWpGaD
Fenoldopam—ADRA1A—Signaling Pathways—AKT1—melanoma	1.75e-05	2.42e-05	CbGpPWpGaD
Fenoldopam—ADRA2A—Signaling Pathways—AKT1—melanoma	1.62e-05	2.25e-05	CbGpPWpGaD
